Literature DB >> 27727216

Rekindling cancer vaccines.

Malorye Allison Branca.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27727216     DOI: 10.1038/nbt.3690

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  13 in total

1.  Nature Biotechnology's academic spinouts of 2015.

Authors:  Aaron Bouchie; Laura DeFrancesco
Journal:  Nat Biotechnol       Date:  2016-05-06       Impact factor: 54.908

2.  Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy.

Authors:  Eric R Lutz; Heather Kinkead; Elizabeth M Jaffee; Lei Zheng
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

3.  Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.

Authors:  James L Gulley; Philip M Arlen; Anne Bastian; Steven Morin; Jennifer Marte; Patricia Beetham; Kwong-Yok Tsang; Junko Yokokawa; James W Hodge; Cynthia Ménard; Kevin Camphausen; C Norman Coleman; Francis Sullivan; Seth M Steinberg; Jeffrey Schlom; William Dahut
Journal:  Clin Cancer Res       Date:  2005-05-01       Impact factor: 12.531

4.  Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.

Authors:  Eric Tran; Simon Turcotte; Alena Gros; Paul F Robbins; Yong-Chen Lu; Mark E Dudley; John R Wunderlich; Robert P Somerville; Katherine Hogan; Christian S Hinrichs; Maria R Parkhurst; James C Yang; Steven A Rosenberg
Journal:  Science       Date:  2014-05-09       Impact factor: 47.728

5.  A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.

Authors:  Caroline Jochems; Jo A Tucker; Kwong-Yok Tsang; Ravi A Madan; William L Dahut; David J Liewehr; Seth M Steinberg; James L Gulley; Jeffrey Schlom
Journal:  Cancer Immunol Immunother       Date:  2014-02-11       Impact factor: 6.968

6.  Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.

Authors:  Edward Cha; Mark Klinger; Yafei Hou; Craig Cummings; Antoni Ribas; Malek Faham; Lawrence Fong
Journal:  Sci Transl Med       Date:  2014-05-28       Impact factor: 17.956

7.  Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.

Authors:  Dung T Le; Eric Lutz; Jennifer N Uram; Elizabeth A Sugar; Beth Onners; Sara Solt; Lei Zheng; Luis A Diaz; Ross C Donehower; Elizabeth M Jaffee; Daniel A Laheru
Journal:  J Immunother       Date:  2013-09       Impact factor: 4.456

8.  Clonotypic Diversification of Intratumoral T Cells Following Sipuleucel-T Treatment in Prostate Cancer Subjects.

Authors:  Nadeem Sheikh; Jason Cham; Li Zhang; Todd DeVries; Simon Letarte; Jeff Pufnock; David Hamm; James Trager; Lawrence Fong
Journal:  Cancer Res       Date:  2016-05-23       Impact factor: 12.701

9.  Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer.

Authors:  Lawrence Fong; Peter Carroll; Vivian Weinberg; Stephen Chan; Jera Lewis; John Corman; Christopher L Amling; Robert A Stephenson; Jeffrey Simko; Nadeem A Sheikh; Robert B Sims; Mark W Frohlich; Eric J Small
Journal:  J Natl Cancer Inst       Date:  2014-09-24       Impact factor: 13.506

10.  Signatures of mutational processes in human cancer.

Authors:  Ludmil B Alexandrov; Serena Nik-Zainal; David C Wedge; Samuel A J R Aparicio; Sam Behjati; Andrew V Biankin; Graham R Bignell; Niccolò Bolli; Ake Borg; Anne-Lise Børresen-Dale; Sandrine Boyault; Birgit Burkhardt; Adam P Butler; Carlos Caldas; Helen R Davies; Christine Desmedt; Roland Eils; Jórunn Erla Eyfjörd; John A Foekens; Mel Greaves; Fumie Hosoda; Barbara Hutter; Tomislav Ilicic; Sandrine Imbeaud; Marcin Imielinski; Marcin Imielinsk; Natalie Jäger; David T W Jones; David Jones; Stian Knappskog; Marcel Kool; Sunil R Lakhani; Carlos López-Otín; Sancha Martin; Nikhil C Munshi; Hiromi Nakamura; Paul A Northcott; Marina Pajic; Elli Papaemmanuil; Angelo Paradiso; John V Pearson; Xose S Puente; Keiran Raine; Manasa Ramakrishna; Andrea L Richardson; Julia Richter; Philip Rosenstiel; Matthias Schlesner; Ton N Schumacher; Paul N Span; Jon W Teague; Yasushi Totoki; Andrew N J Tutt; Rafael Valdés-Mas; Marit M van Buuren; Laura van 't Veer; Anne Vincent-Salomon; Nicola Waddell; Lucy R Yates; Jessica Zucman-Rossi; P Andrew Futreal; Ultan McDermott; Peter Lichter; Matthew Meyerson; Sean M Grimmond; Reiner Siebert; Elías Campo; Tatsuhiro Shibata; Stefan M Pfister; Peter J Campbell; Michael R Stratton
Journal:  Nature       Date:  2013-08-14       Impact factor: 49.962

View more
  13 in total

Review 1.  Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer-where are we?

Authors:  Matthew Evans; Brendan O'Sullivan; Matthew Smith; Philippe Taniere
Journal:  Transl Lung Cancer Res       Date:  2018-12

2.  Erratum: Rekindling cancer vaccines.

Authors:  Malorye Allison Branca
Journal:  Nat Biotechnol       Date:  2016-12-07       Impact factor: 54.908

3.  Systemic and local immunosuppression in patients with high-grade meningiomas.

Authors:  Yuping D Li; Dorina Veliceasa; Jason B Lamano; Jonathan B Lamano; Gurvinder Kaur; Dauren Biyashev; Craig M Horbinski; Tim J Kruser; Orin Bloch
Journal:  Cancer Immunol Immunother       Date:  2019-04-27       Impact factor: 6.968

Review 4.  Bioinspired nucleic acid structures for immune modulation.

Authors:  Cameron Louttit; Kyung Soo Park; James J Moon
Journal:  Biomaterials       Date:  2019-06-19       Impact factor: 12.479

Review 5.  Emerging role of natural products in cancer immunotherapy.

Authors:  Songtao Dong; Xiangnan Guo; Fei Han; Zhonggui He; Yongjun Wang
Journal:  Acta Pharm Sin B       Date:  2021-08-21       Impact factor: 14.903

6.  Therapeutic vaccination against leukaemia via the sustained release of co-encapsulated anti-PD-1 and a leukaemia-associated antigen.

Authors:  Xiaoling Xie; Yuxing Hu; Tong Ye; Yiran Chen; Lijuan Zhou; Feng Li; Xiaobo Xi; Shuang Wang; Yanjie He; Xiaoyong Gao; Wei Wei; Guanghui Ma; Yuhua Li
Journal:  Nat Biomed Eng       Date:  2020-10-12       Impact factor: 25.671

7.  Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor.

Authors:  Flavia Fontana; Manlio Fusciello; Christianne Groeneveldt; Cristian Capasso; Jacopo Chiaro; Sara Feola; Zehua Liu; Ermei M Mäkilä; Jarno J Salonen; Jouni T Hirvonen; Vincenzo Cerullo; Hélder A Santos
Journal:  ACS Nano       Date:  2019-05-17       Impact factor: 15.881

8.  Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors.

Authors:  Dmitry M Ponomarenko; Irina D Klimova; Yulia A Chapygina; Viktoria V Dvornichenko; Natalia V Zhukova; Rashida V Orlova; Georgy M Manikhas; Alexandr V Zyryanov; Lilya A Burkhanova; Irina I Badrtdinova; Basile N Oshchepkov; Elena V Filippova; Sergei V Orlov; Sergei I Kolesnikov; Albert A Sufianov; Svetlana R Baum; Olga Y Zaitzeva; Andrey B Komissarov; Mikhail P Grudinin; Oleg I Kiselev; Anatoly F Tsyb; Franco Venanzi; Vita Shcherbinina; Andrey Chursov; Vladimir L Gabai; Alexander M Shneider
Journal:  Oncotarget       Date:  2017-03-25

9.  Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning.

Authors:  Jonathan G Pol; Matthew J Atherton; Kyle B Stephenson; Byram W Bridle; Samuel T Workenhe; Natasha Kazdhan; Aj Robert McGray; Yonghong Wan; Guido Kroemer; Brian D Lichty
Journal:  J Immunother Cancer       Date:  2020-08       Impact factor: 13.751

Review 10.  Computational Prediction and Validation of Tumor-Associated Neoantigens.

Authors:  Vladimir Roudko; Benjamin Greenbaum; Nina Bhardwaj
Journal:  Front Immunol       Date:  2020-01-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.